**Background:** The rapid development of SARS-CoV-2 vaccines has been a major achievement in the COVID-19 pandemic, with over 2.15 billion doses administered globally by June 2021. However, the emergence of variants of concern (VOCs)—particularly Alpha, Beta, Gamma, Delta, and Omicron—has raised concerns about vaccine effectiveness. The Omicron variant (B.1.1.529) contains more than 30 mutations in the spike protein, many in the receptor-binding domain (RBD) and N-terminal domain (NTD), which are associated with enhanced ACE2 receptor binding, immune escape from neutralizing antibodies (NAbs), and altered cellular tropism favoring the endosomal entry pathway over TMPRSS2-mediated plasma membrane entry. This review synthesizes evidence on how these mutations influence vaccine-induced immunity and explores strategies to overcome variant-driven challenges.
**Methods:** This is a narrative review summarizing published data on SARS-CoV-2 variant classification, mutational dynamics, and vaccine effectiveness. The authors describe key spike protein mutations (e.g., N501Y, E484K, H69-V70 deletion, Y144/145 deletion, D614G, L452R, T478K, E484A, Q498R) and their functional consequences. Variant classification follows WHO and CDC categories: variants of interest (VOIs), variants of concern (VOCs), and variants of high consequence (VOHCs). Vaccine effectiveness data are drawn from published clinical trials and observational studies for multiple vaccine platforms, including mRNA (BNT162b2/Pfizer-BioNTech, mRNA-1273/Moderna), adenoviral vector (ChAdOx1 nCoV-19/AstraZeneca, Ad26.COV2.S/Johnson & Johnson), inactivated whole-virion (BBV152/Covaxin), and protein subunit (NVX-CoV2373/Novavax) vaccines.
**Key Results:** The review reports that NAbs in sera from recipients of two-dose Ad26.COV2.S were considerably less efficient against Omicron than the original strain, with a dramatic decline in antibody-mediated immune response (20 × 10² vs. 184 × 10³ on day 8 post-vaccination). Serum neutralizing ability of BNT162b2 recipients was diminished 35-fold against BA.1 compared to the D614G variant, and was not effective against BA.2 and BA.3. For mRNA-1273, neutralization titers against Omicron were 35 times lower than against D614G after two doses; however, a booster dose increased titers 20-fold. Edara et al. reported a 30-fold decrease in neutralizing activity against Omicron 2–4 weeks after primary immunization, with no neutralizing activity detected six months after two doses; a booster restored activity but with a 14-fold reduction. ChAdOx1 nCoV-19 showed effectiveness of 74.5% against Alpha, 67.0% against Delta, and 77.9% against Gamma, but only 10.4% against Beta. BBV152 (Covaxin) showed 77.8% efficacy against symptomatic cases and 68.2% against Delta in a Phase III trial, but convalescent sera could not neutralize the P.1 (Gamma) lineage. Two doses of BNT162b2 were 88% effective against Alpha and 88% against Delta; two doses of ChAdOx1 nCoV-19 were 74.5% effective against Alpha and 67.0% against Delta. In a study of 192,123 participants receiving two doses of mRNA-1273 vs. BNT162b2, breakthrough infections numbered 878 and 1,262, respectively, with seven severe cases and one death in the BNT162b2 group. The review also notes that cellular immunity (CD8+ and CD4+ T cell responses) is largely conserved against Omicron, particularly after BNT162b2 vaccination.
**Clinical Implications:** The emergence of VOCs, especially Omicron, has significantly compromised the neutralizing antibody response elicited by current vaccines, though booster doses partially restore protection. The review emphasizes that inactivated whole-virion vaccines (e.g., BBV152) may offer advantages due to their ability to present multiple epitopes beyond the spike protein, potentially providing broader cross-neutralization. Intranasal vaccines (e.g., BBV154) are highlighted as a promising strategy to induce mucosal IgA and T cell responses at the primary site of viral entry. The authors advocate for pan-coronavirus or pan-SARS-CoV-2 booster vaccines, stabilized pre-fusion spike protein designs (e.g., S-2P and HexaPro), and RBD-dimer or multimerization approaches to enhance immunogenicity. The review underscores the need for rapid diagnostic tools, continuous genomic surveillance, and adaptable vaccine platforms to address ongoing viral evolution and breakthrough infections.